6 terminated, 6 unknown, 4 completed, 1 recruiting. 17 Phase 2, 7 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Terminated 6, Unknown 6, Completed 4, Recruiting 1 |
| Phase 1 | 7 | Terminated 4, Unknown 2, Completed 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Cancer of Pancreas: new trials by email Literature Review of Cancer of Pancreas trials Research Report on Cancer of Pancreas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors CBP-1019 - Cancer, Breast, Cancer, Lung | Phase 1 / Phase 2 | Unknown | Coherent Biopharma (Hefei) Co., Ltd. | 260 | 2023-03-14 | 2024-08-26 |
| A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas Capecitabine, follow up - Cancer of Pancreas | Phase 2 | Unknown | Menoufia University | 40 | 2022-09-11 | 2022-10-04 |
| Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN) Gemcitabine fluorouracil - Cancer of Pancreas, Chemotherapy Effect | Phase 2 | Completed | Menoufia University | 48 | 2021-02-20 | 2022-08-08 |
| Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer Oxaliplatin, Leucovorin, Irinotecan Hydrochloride - Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 45 | 2019-06-12 | 2026-01-13 |
| Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients 68GaNOTA-Anti-HER2 VHH1 - Metastatic Breast Carcinoma, Locally Advanced Breast Cancer | Phase 2 | Unknown | Universitair Ziekenhuis Brussel | 55 | 2019-04-01 | 2024-02-16 |
| A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies Cannabidiol, Bortezomib, Leucovorin - Cancer of Pancreas, Cancer of Liver | Phase 1 / Phase 2 | Unknown | Leaf Vertical Inc. | 160 | 2019-01-15 | 2018-07-31 |
| Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer Bemcentinib, Nab-paclitaxel, Gemcitabine - Cancer of Pancreas | Phase 1 / Phase 2 | Terminated | University of Texas Southwestern Medical Center | 9 | 2019-01-03 | 2023-11-09 |
| A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1) Gemcitabine, nab-paclitaxel, Pharmacological ascorbate - Pancreatic Neoplasms, Cancer of Pancreas | Phase 2 | Completed | University of Iowa | 40 | 2018-11-28 | 2026-07-23 |
| M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas M7824, Gemcitabine - Cancer of Pancreas, Pancreas Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 7 | 2018-05-17 | 2021-06-16 |
| Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma Preoperative chemotherapy, Preoperative radiotherapy - Cancer of Pancreas, Pancreas Adenocarcinoma | Phase 2 | Terminated | CNAO National Center of Oncological Hadrontherapy | 30 | 2018-02-08 | 2025-02-13 |
| Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients Nab-paclitaxel plus Gemcitabine, Gemcitabine monotherapy, S-1 monotherapy - Cancer of Pancreas | Phase 2 | Unknown | Chinese PLA General Hospital | 90 | 2017-10-01 | 2017-09-11 |
| Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer Nintedanib - Cancer of Pancreas | Phase 1 / Phase 2 | Terminated | University of Texas Southwestern Medical Center | 14 | 2017-09-07 | 2024-06-03 |
| Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer Patients will receive initial chemotherapy, followed by evaluation of the response to the treatment, followed by SBRT, followed by chemotherapy. - Cancer of Pancreas, Unresectable Pancreatic Cancer | Phase 2 | Completed | Medical University of Silesia | 40 | 2017-01-01 | 2019-11-13 |
| Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma Tosedostat, Capecitabine, Fresh tissue biopsy - Pancreatic Cancer, Cancer of Pancreas | Phase 1 / Phase 2 | Terminated | Washington University School of Medicine | 16 | 2015-08-31 | 2019-08-28 |
| Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer Durvalumab, Tremelimumab, Sterostatic body radiation therapy (SBRT) - Pancreatic Neoplasms, Pancreatic Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 65 | 2015-03-25 | 2021-04-20 |
| Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas FOLFIRINOX + CRT - Cancer of Pancreas | Phase 2 / Phase 3 | Unknown | Assiut University | 1 | 2014-10-01 | 2014-12-08 |
| Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint Gemcitabine, panitumumab - Cancer of Pancreas, Cancer of the Pancreas | Phase 2 | Terminated | Amgen | 3 | 2007-01-01 | 2014-01-06 |
Pancreatic Neoplasms (17) · Adenocarcinoma (2) · Breast Neoplasms (2) · Colonic Neoplasms (2) · Biliary Tract Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Gallbladder Neoplasms (1) · Glioblastoma (1) · Liver Neoplasms (1) · Lung Neoplasms (1)
Digestive System Diseases (17) · Digestive System Neoplasms (17) · Endocrine Gland Neoplasms (17) · Endocrine System Diseases (17) · Neoplasms by Site (17) · Pancreatic Diseases (17) · Neoplasms (16) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Carcinoma (3) · Colonic Diseases (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Intestinal Diseases (3) · Intestinal Neoplasms (3)
Gemcitabine (6) · Fluorouracil (4) · Irinotecan (4) · Oxaliplatin (4) · 130-nm albumin-bound paclitaxel (3) · Leucovorin (3) · Albumin-Bound Paclitaxel (2) · Capecitabine (2) · Ascorbic Acid (1) · Bevacizumab (1) · Bortezomib (1) · Cannabidiol (1) · Cisplatin (1) · Heavy Ion Radiotherapy (1) · Injections (1)
Menoufia University (2) · National Cancer Institute (NCI) (2) · University of Texas Southwestern Medical Center (2) · Amgen (1) · Assiut University (1) · CNAO National Center of Oncological Hadrontherapy (1) · Chinese PLA General Hospital (1) · Coherent Biopharma (Hefei) Co., Ltd. (1) · Leaf Vertical Inc. (1) · Medical University of Silesia (1) · UNC Lineberger Comprehensive Cancer Center (1) · Universitair Ziekenhuis Brussel (1) · University of Iowa (1) · Washington University School of Medicine (1)
United States (9) · Egypt (3) · China (2) · Belgium (1) · Italy (1) · Poland (1)
Andrea Wang-Gillam, M.D., Ph.D. (1) · Ashwin Somasundaram, MD (1) · Francesca Valvo, MD (1) · Joseph J. Cullen, MD, FACS (1) · Lin Shen, MD (1) · Nahla Atef Shabaan, Master (1) · Salwan Al Mutar, MD (1) · Sarah F Katta, DO (1) · Syed Kazmi, MD (1) · Tim F Greten, M.D. (1) · Udo Rudloff, M.D. (1)
PMID 31521134, PMID 39369582, PMID 39462835
2016 (1), P01CA217797 (1), P30CA086862 (1), U01CA140206 (1)